| Literature DB >> 27651314 |
Elina Timosenko1, Hemza Ghadbane1, Jonathan D Silk1, Dawn Shepherd1, Uzi Gileadi1, Lauren J Howson1, Robert Laynes2, Qi Zhao3, Robert L Strausberg3, Lars R Olsen4, Stephen Taylor5, Francesca M Buffa6, Richard Boyd2, Vincenzo Cerundolo7.
Abstract
Tryptophan degradation is an immune escape strategy shared by many tumors. However, cancer cells' compensatory mechanisms remain unclear. We demonstrate here that a shortage of tryptophan caused by expression of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) resulted in ATF4-dependent upregulation of several amino acid transporters, including SLC1A5 and its truncated isoforms, which in turn enhanced tryptophan and glutamine uptake. Importantly, SLC1A5 failed to be upregulated in resting human T cells kept under low tryptophan conditions but was enhanced upon cognate antigen T-cell receptor engagement. Our results highlight key differences in the ability of tumor and T cells to adapt to tryptophan starvation and provide important insights into the poor prognosis of tumors coexpressing IDO and SLC1A5. Cancer Res; 76(21); 6193-204. ©2016 AACR. ©2016 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27651314 PMCID: PMC5096689 DOI: 10.1158/0008-5472.CAN-15-3502
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701